Intellia Therapeutics Inc buy Savour
Start price
24.01.21
/
20%
€63.50
Target price
24.01.22
-
Performance (%)
-15.72%
End price
11.03.21
€53.52
Summary
This prediction ended on 11.03.21 with a price of €53.52. The price of Intellia Therapeutics Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -15.72%. Savour has 20% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Intellia Therapeutics Inc | -0.426% | -0.426% | -5.721% | -73.811% |
| iShares Core DAX® | 2,33 % | 1,01 % | 10,41 % | 61,23 % |
| iShares Nasdaq 100 | 1,37 % | -3,61 % | 27,40 % | 80,08 % |
| iShares Nikkei 225® | 2,44 % | -7,46 % | 49,84 % | 72,35 % |
| iShares S&P 500 | 1,26 % | 0,68 % | 23,67 % | 65,89 % |
According to Savour what are the pros and cons of Intellia Therapeutics Inc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by Savour for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Buy Intellia Therapeutics Inc